Sugi Predict

Sugi Predict / Compounds / SCHEMBL8102998

SCHEMBL8102998

SCHEMBL8102998

CC(C)(C)C(=O)NC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.59

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 6/20 0.59
▸ EPHX1 P07099 2/20 0.59
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ CACNA1H O95180 3/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ GAA P10253 1/20 0.49
▸ SIGMAR1 Q99720 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17586273 0.91 EPHX2 (0.46) EPHX2EPHX1KMT2AMEN1MAPK1
SCHEMBL11959258 0.84 EPHX2 (0.55) EPHX2EPHX1KMT2AMEN1MAPK1
SCHEMBL11941695 0.81 KMT2A (0.53) EPHX2EPHX1KMT2AMEN1MAPK1
SCHEMBL14008167 0.79 EPHX2 (0.59) EPHX2EPHX1KMT2AMEN1SMN1; SMN2
SCHEMBL13432096 0.79 EPHX2 (0.59) EPHX2EPHX1KMT2AMEN1SMN1; SMN2
SCHEMBL7353899 0.79 EPHX2 (0.59) EPHX2EPHX1KMT2AMEN1SMN1; SMN2
SCHEMBL22480390 0.76 EPHX2 (0.67) EPHX2EPHX1KMT2AMEN1MAPK1
SCHEMBL29103915 0.76 EPHX2 (0.55) EPHX2EPHX1KMT2AMEN1SMN1; SMN2
SCHEMBL19757636 0.76 EPHX1 (0.68) EPHX2EPHX1KMT2ASMN1; SMN2GAA
SCHEMBL133014 0.76 EPHX1 (0.68) EPHX2EPHX1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 — — US disclosed
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 — — US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 — — US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed
US-7244847-B2 Benzimidazole compounds ISIS PHARMACEUTICALS, INC. (US) 2007-07-17 — — US disclosed
US-7244847-B2 Benzimidazole compounds ISIS PHARMACEUTICALS, INC. (US) 2007-07-17 — — US disclosed
US-7220532-B2 Chemical amplification type resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-22 — — US disclosed
US-7220532-B2 Chemical amplification type resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 EPHX2 3047/4885EPHX1 2531/4885KMT2A 1510/4885
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS SPR, QDPR, SRR EPHX2 1398/4885EPHX1 950/4885KMT2A 2884/4885
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 EPHX2 1053/4885EPHX1 2408/4885KMT2A 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.